EP 2515872 A1 20121031 - ORAL FORM OF ADMINISTRATION COMPRISING ENTECAVIR
Title (en)
ORAL FORM OF ADMINISTRATION COMPRISING ENTECAVIR
Title (de)
ORALE DARREICHUNGSFORM UMFASSEND ENTECAVIR
Title (fr)
FORME D'ADMINISTRATION ORALE CONTENANT DE L'ENTECAVIR
Publication
Application
Priority
- DE 102009060194 A 20091223
- DE 102010048635 A 20101015
- EP 2010007892 W 20101222
Abstract (en)
[origin: WO2011076412A1] The invention relates to pharmaceutical formulations, preferably in the form of an oral administration, for treating chronic hepatitis B viral infections, containing micronized entecavir, and to a method for the production thereof. The invention further relates to intermediates, containing micronized entecavir, in which the D50 value of the particle size distribution is smaller than 50 µm, and to a method for the production thereof.
IPC 8 full level
A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 31/52 (2006.01)
CPC (source: EP US)
A61K 9/145 (2013.01 - EP US); A61K 9/146 (2013.01 - EP US); A61K 9/2009 (2013.01 - EP US); A61K 9/2018 (2013.01 - EP US); A61K 9/2054 (2013.01 - EP US); A61K 9/2059 (2013.01 - EP US); A61K 9/2095 (2013.01 - EP US); A61K 31/52 (2013.01 - EP US); A61P 31/14 (2017.12 - EP)
Citation (search report)
See references of WO 2011076412A1
Citation (examination)
U S INITIAL: "FULL PRESCRIBING INFORMATION: CONTENTS* WARNINGS: SEVERE ACUTE EXACERBATIONS OF HEPATITIS B, PATIENTS CO-INFECTED WITH HIV AND HBV, AND LACTIC ACIDOSIS AND HEPATOMEGALY 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 Renal Impairment 2.3 Hepatic Impairment 2.4 Duration", 1 January 2005 (2005-01-01), XP055293493, Retrieved from the Internet <URL:http://web.archive.org/web/20090220143435/http://packageinserts.bms.com/pi/pi_baraclude.pdf>
Citation (third parties)
Third party :
- WO 2008098471 A1 20080821 - ZHEJIANG MEDICINE CO LTD [CN], et al
- RAWLE, A.: "Basic principles of particle size analysis", MALVERN INSTRUMENTS LIMITED, 2008, pages 1 - 8, XP055009141
- STORTI, F. ET AL.: "Particle size distributions by laser diffraction: sensitivity of granular matter strength to analytical operating procedures", SOLID EARTH, vol. 1, 2010, pages 25 - 48, XP003027683
- LIEBERMAN, H.A. ET AL.: "Pharmaceutical dosage forms: Tablets (Second edition, revised and expanded", vol. 2, 1989, article RUSSELL J. LANTZ, JR.: "Size reduction", pages: 107 - 200, XP008059470
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2011076412 A1 20110630; EA 201290556 A1 20130130; EP 2515872 A1 20121031; US 2012308652 A1 20121206
DOCDB simple family (application)
EP 2010007892 W 20101222; EA 201290556 A 20101222; EP 10798016 A 20101222; US 201013517981 A 20101222